Create account

Coverage dated October 4, 2021

AstraZeneca asks FDA to authorize antibody treatment to prevent COVID-19

Headline from FOX 5 New York

AstraZeneca said the treatment would be the first long-acting antibody combination to receive an emergency use authorization for COVID-19 prevention.

FOX 5 New York's own description from its feed. We collect headlines and these descriptions, not full articles; read the original reporting below.

Read the reports

Reports & sources

29 articles, oldest first.

  1. FOX 5 New York

    AstraZeneca asks FDA to authorize antibody treatment to prevent COVID-19 (opens FOX 5 New York)

    Published

    FOX 5 New York's feed description

    AstraZeneca said the treatment would be the first long-acting antibody combination to receive an emergency use authorization for COVID-19 prevention.

  2. NBC4 Washington

    AstraZeneca Asks FDA to Authorize COVID Antibody Treatment (opens NBC4 Washington)

    Published

    NBC4 Washington's feed description

    AstraZeneca, the Anglo-Swedish drugmaker that developed one of the first COVID-19 vaccines, has asked the U.S. Food and Drug Administration to authorize the emergency use of an antibody treatment to prevent the disease.

  3. New York Times

    AstraZeneca asks the F.D.A. to authorize an antibody treatment to prevent Covid-19. (opens New York Times)

    Published

    New York Times's feed description

    The company said the treatment had cut the risk of symptomatic Covid in patients with conditions that put them at high risk, or who had not responded well to a vaccine.

  4. Newsweek

    AstraZeneca asks FDA to approve COVID antibody drug for those with weakened immune systems (opens Newsweek)

    Published

    Newsweek's feed description

    Late-stage human trials showed that AstraZeneca's antibody drug reduced the risk of developing symptomatic COVID-19 by 77 percent.

  5. NBC News

    AstraZeneca asks FDA to authorize Covid antibody treatment to prevent illness (opens NBC News)

    Published

    NBC News's feed description

    If authorized, it would be the first long-acting drug for people with compromised immune systems who don't get sufficient protection from vaccination.

Identical headlines usually mean shared wire copy. They are counted as separate articles but are not independent confirmation.

AstraZeneca asks FDA to authorize antibody treatment to prevent COVID-19 | Since Then